×
About 18,125 results

ALLMedicine™ Bilirubin Center

Research & Reviews  5,787 results

Almond oil restores blood parameters, liver function, blood and liver antioxidants and ...
https://doi.org/10.1515/jcim-2022-0086
Journal of Complementary & Integrative Medicine; Koriem KMM, El-Attar MA

Jun 26th, 2022 - Favism is a metabolic disease and this study aimed to compare between olive oil and almond oil to ameliorate blood parameters, liver function, blood and liver antioxidants and DNA, and liver histology in favism rats. Animals were 36 male albino ra...

Children undergoing early liver re-transplantation for primary non-function have improv...
https://doi.org/10.1111/petr.14347
Pediatric Transplantation; Rogers ME, Delman A et. al.

Jun 26th, 2022 - Primary non-function (PNF) in the early post-LT period in children leads to prolonged hospitalization, high graft loss, and significant mortality. However, there is a paucity of data available on the natural history of children relisted for LT due...

Receipt of at least 4 units of low titer group O whole blood with titer <100 does not l...
https://doi.org/10.1111/trf.16980
Transfusion Yazer MH, Corcos A et. al.

Jun 25th, 2022 - The serological safety of transfusing low titer group O whole blood (LTOWB) with an anti-A and anti-B titer of <100 was evaluated in group O and non-group O trauma recipients. Civilian adult trauma patients who received ≥4 units of leukoreduced LT...

Population Pharmacokinetics of Tigecycline: A Systematic Review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211078
Drug Design, Development and Therapy; Zhou CC, Huang F et. al.

Jun 25th, 2022 - Although tigecycline is widely used in clinical practice, its efficiency and optimal dosage regimens remain controversial. The purpose of this article was to help guide tigecycline dosing in different patient subpopulations through comparing the p...

see more →

Guidelines  7 results

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment an...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109281
Gut Hirschfield GM, Dyson JK et. al.

Mar 30th, 2018 - Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an en...

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
https://doi.org/10.1038/ajg.2016.517
The American Journal of Gastroenterology; Kwo PY, Cohen SM et. al.

Dec 21st, 2016 - Clinicians are required to assess abnormal liver chemistries on a daily basis. The most common liver chemistries ordered are serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and bilirubin. These tests sh...

Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendations ...
https://doi.org/10.1097/MPG.0000000000001334
Journal of Pediatric Gastroenterology and Nutrition; Fawaz R, Baumann U et. al.

Jul 19th, 2016 - Cholestatic jaundice in infancy affects approximately 1 in every 2500 term infants and is infrequently recognized by primary providers in the setting of physiologic jaundice. Cholestatic jaundice is always pathologic and indicates hepatobiliary dy...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Ata...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785051
Clinical Pharmacology and Therapeutics; Gammal RS, Court MH et. al.

Sep 30th, 2015 - The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can c...

Prevention of acute bilirubin encephalopathy and kernicterus in newborns: position stat...
https://doi.org/10.1097/ANC.0b013e31822efd64
Advances in Neonatal Care : Official Journal of the Natio...

Dec 14th, 2011 - Prevention of acute bilirubin encephalopathy and kernicterus in newborns: position statement #3049.|2011| ,|blood,complications,diagnosis,prevention & control,etiology,prevention & control,methods,

see more →

Drugs  130 results see all →

Clinicaltrials.gov  843 results

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03976843

Jun 24th, 2022 - Background: About 30,000 men will die from prostate cancer in the US in 2018. The majority of these men originally presented with localized cancer. Treatment options for patients with high risk, localized disease typically involve radical prostate...

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
https://clinicaltrials.gov/ct2/show/NCT02759731

Jun 24th, 2022 - Background: Chronic graft-versus-host disease (cGVHD) is the leading cause of non-relapse morbidity and mortality in persons after allogeneic hematopoietic stem cell transplantation (SCT). Approximately 50% of patients with cGVHD have disease refr...

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT01130519

Jun 24th, 2022 - Background Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a familial cancer syndrome characterized by a propensity for developing renal cancer, and uterine and cutaneous leiomyomas. The kidney cancer associated with HLRCC is clinically...

Characterization of Pre-Term Neonatal Skin
https://clinicaltrials.gov/ct2/show/NCT05127044

Jun 21st, 2022 - This is a cross-sectional, pilot study to characterize the response of neonatal premature skin to DRS when excited with a white light source, and provide a baseline of how the collected spectra change with the maturation of the epidermal layer in ...

Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal...
https://clinicaltrials.gov/ct2/show/NCT03666832

Jun 15th, 2022 - Inclusion Subjects who are males or females ≥ 19 years of age Subjects who have the following history of first-line gemcitabine and nab-paclitaxel among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcino...

see more →

News  475 results

Sex-Adjusted Liver Allocation Scoring Tool Would Improve Transplant Equity
https://www.medscape.com/viewarticle/974849

Jun 1st, 2022 - NEW YORK (Reuters Health) - Females on the liver transplant waiting list are disadvantaged by the sodium-adjusted Model for End-stage Liver Disease score (MELDNa) currently employed to guide allocation decisions, but a sex-adjusted MELDNa score wo...

In Patients With CBD Stones, Cholecystectomy Wound Infection Rates Similar With Broad- vs Narrow-Spectrum Antibiotics
https://www.medscape.com/viewarticle/974231

May 19th, 2022 - NEW YORK (Reuters Health) - In patients with common bile duct (CBD) stones undergoing same-admission cholecystectomy, surgical site infection rates are low and similar with broad- and narrow-spectrum antibiotics, observational data suggest. Patien...

Selecting Second-Line Therapy for Chronic GVHD
https://www.onclive.com/view/selecting-second-line-therapy-for-chronic-gvhd

May 3rd, 2022 - Transcript: Yi-Bin Chen, MD: Excitingly, we now have 3 agents approved in steroid-refractory chronic graft-vs-host disease [GVHD]. It started several years back, when ibrutinib, the oral BTK [Bruton tyrosine kinase] inhibitor, was approved target...

Tenofovir vs. entecavir: Better therapeutic in HBV-related HCC after radiofrequency ablation
https://www.mdedge.com/fedprac/article/254135/hepatocellular-carcinoma/tenofovir-vs-entecavir-better-therapeutic-hbv

Apr 26th, 2022 - Key clinical point: In patients with hepatitis B virus ( HBV)-related hepatocellular carcinoma (HCC ) who had undergone radiofrequency ablation (RFA), tenofovir disoproxil fumarate (TDF) performed better at protecting liver function and reducing H.

European Approval Sought for Ivosidenib in IDH1-Mutated AML and Cholangiocarcinoma
https://www.onclive.com/view/european-approval-sought-for-ivosidenib-in-idh1-mutated-aml-and-cholangiocarcinoma

Apr 22nd, 2022 - A marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for 2 indications of ivosidenib (Tibsovo): in combination with azacitidine in the frontline treatment of patients with IDH1-mutated acute myeloid...

see more →

Patient Education  8 results see all →